How we perform a guided biopsy of the prostate;Comment nous faisons une biopsie de prostate

Feuillets de Radiologie

Volumn 45, Issue 4, 2005, Pages 297-307

  Cornud, F ^a   Peyromaure, M ^a   Vieillefond, A ^a   Zerbib, M ^a   Flam, T ^a   Chevrot, A ^a  

^a université Paris Cité   (France)

Author keywords

Biopsies; Cancer; MRI; Prostate; Sonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SPECTROSCOPY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 26444476398     PISSN: 01819801     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-9801(05)80606-2     Document Type: Review

References (59)

1. Rifkin MD, Archibald AA, Pisarchick J, Matteucci T. Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy. Radiology 1991; 179: 41-2.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
3. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996; 156: 350-4.
4. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4.
5. Villers A, Mouton D, Rebillard X, Chautard D, Ruffion A, Staerman F et al. Biopsy technique and biopsy schemes for a first series of prostatic biopsies. Prog Urol 2004; 14: 144-53.
6. Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001; 166: 82-5.
7. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85: 682-5.
8. Griffith BC, Morey AF, Ali-Khan MM, Canby-Hagino E, Foley JP, Rozanski TA. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol 2002; 168: 1021-3.
9. Desgrandchamps F, Meria P, Irani J, Desgrippes A, Teillac P, Le Due A. The rectal administration of lidocaine gel and tolerance of transrectal ultrasonography-guided biopsy of the prostate: a prospective randomized placebo-controlled study. BJU Int 1999; 83: 1007-9.
10. Issa MM, Bux S, Chun T, Petros JA, Labadia AJ, Anastasia K et al. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience. J Urol 2000; 164: 397-9.
11. Schostak M, Christoph F, Muller M, Heicappell R, Goessl G, Staehler M et al. Optimizing local anesthesia during 10-core biopsy of the prostate. Urology 2002; 60: 253-7.
12. Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 1995; 45: 987-92.
13. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002; 167: 2032-6.
14. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75: 530-8.
15. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994; 44: 371-6.
16. Cornud F, Belin X, Piron D, Chretien Y, Flam T, Casanova JM et al. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. Urology 1997; 49: 709-15.
17. Cornud F. Imagerie de contraste de la prostate. In: Cornud F, editor. Imagerie de la prostate. Paris: Sauramps Medical; 2004.
18. Louvar E, Littrup PJ, Goldstein A, Yu L, Sakr W, Grignon D. Correlation of color Doppler flow in the prostate with tissue microvascularity. Cancer 1998; 83: 135-40.
19. Cornud F, Oyen R. Role of imaging in the diagnosis and staging of prostatic adenocarcinomas. J Radiol 2002; 83: 863-82.
20. Spencer JA, Alexander AA, Gomella L, Matteucci T, Goldberg BB. Clinical and US findings in prostate cancer: patients with normal prostate-specific antigen levels. Radiology 1993; 189: 89-93.
21. Brawer MK. Prostate-specific antigen. Semin Surg Oncol 2000; 18: 3-9.
22. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 1993; 20: 671-80.
23. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
24. Orozco R, Kunnel B, O'Dowd GJ, Stamey TA. Positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination. Urology 1998; 51: 531-3.
25. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 1993; 20: 665-70.
26. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
27. Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 1997; 157: 189-94.
28. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8.
29. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999; 54: 517-22.
30. Okegawa T, Kinjo M, Watanabe K, Noda H, Kato M, Miyata A et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL. BJU Int 2000; 85: 708-14.
31. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003; 170: 2181-5.
32. Fleshner NE, O'Sullivan M, Premdass C, Fair WR. Clinical significance of small (less than 0.2 cm3) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels less than 10 ng/mL. Urology 1999; 53: 356-8.
33. Frauscher F, Klauser A, Volgger H, Halpern EJ, Pallwein L, Steiner H et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002; 167: 1648-52.
34. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435-9.
35. Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998; 52: 808-13.
36. Mazal PR, Haitel A, Windischberger C, Djavan B, Sedivy R, Moser E et al. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001; 39: 662-8.
37. Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001; 47: 111-7.
38. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-5.
39. Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int 1997; 59: 239-42.
40. Zeng J, Bauer J, Zhang W, Sesterhenn I, Connelly R, Lynch J et al. Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation. Comput Aided Surg 2001; 6: 14-21.
41. Ravery V, Billebaud T, Toublanc M, Boccon-Gibod L, Hermieu JF, Moulinier F et al. Diagnostic value of ten systematic TRUS-guided prostate biopsies. Eur Urol 1999; 35: 298-303.
42. Epstein JI, Walsh PC, Carter HB. Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001; 57: 1112-6.
43. Presti JC, Jr., Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163-7.
44. Cookson MS. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol 2000; 4: 93-9.
45. Brossner C, Bayer G, Madersbacher S, Kuber W, Klingler C, Pycha A. Twelve prostate biopsies detect significant cancer volumes (> 0.5 mL). BJU Int 2000; 85: 705-7.
46. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-203.
47. Chang JJ, Shinohara K, Hovey RM, Montgomery C, Presti JC, Jr. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology 1998; 52: 89-93.
48. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86-92.
49. Jones JS, Oder M, Zippe CD. Saturation prostate biopsy with periprostatic block can be performed in office. J Urol 2002; 168: 2108-10.
50. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage Tie prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J Urol 1997; 157: 244-50.
51. Peyromaure M, Ravery V, Boccon-Gibod L. Biopsies of the transitional zone: impact on the detection of prostatic cancer and prognostic value. Prog Urol 2002; 12: 8-14.
52. Maeda H, Ishitoya S, Aoki Y, Okubo K, Okada T, Maekawa S et al. Value of systematic transition zone biopsy in the detection of prostate cancer. Int J Urol 1997; 4: 567-71.
53. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721-9.
54. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003; 170: 370-2.
55. Molinie V. Prostatic intraepithelial neoplasia. Ann Pathol 2001; 21: 245-54.
56. Shepherd D, Keetch DW, Humphrey PA, Smith DS, Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 1996; 156: 460-3.
57. Lefkowitz GK, Taneja SS, Brown J, Melamed J, Lepor H. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168: 1415-8.
58. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol 1999; 162: 1314-7.
59. Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR Imaging. Radiology 2002; 224: 701-6.